Please check your internet connection and try again.
# Septran (Co-trimoxazole)
## Overview
Septran is a combination antibiotic containing sulfamethoxazole and trimethoprim. It is available in various formulations, including tablets, oral suspension, and intravenous preparations.
## Primary Indications
* Urinary tract infections (UTIs)
* Pneumocystis jirovecii pneumonia (PJP) prophylaxis and treatment
* Traveler's diarrhea
* Certain respiratory tract infections
* Other specific bacterial infections susceptible to co-trimoxazole.
## Adult Dosing
* **Uncomplicated UTIs:** 1 DS (double strength) tablet PO every 12 hours for 3-7 days.
* **PJP Treatment:** 15 mg/kg/day of trimethoprim component divided into 3-4 doses PO or IV, given over 14-21 days.
* **PJP Prophylaxis:** 1 DS tablet PO daily, or 1 DS tablet PO three times weekly.
* **Traveler's Diarrhea:** 1 DS tablet PO every 12 hours for 3-5 days.
* **Maximum dose:** Generally, do not exceed 8 DS tablets (1600 mg sulfamethoxazole / 320 mg trimethoprim) per day for treatment indications, unless treating PJP.
Dosing for other indications and specific formulations should be guided by local protocols and current prescribing information.
## Pediatric Dosing
Dosing is typically based on the trimethoprim component weight-based.
* **UTIs:** 8 mg/kg/day of trimethoprim component, administered in 2 equally divided doses PO every 12 hours for 7-10 days.
* **PJP Treatment:** 15 mg/kg/day of trimethoprim component divided into 3-4 doses PO or IV, given over 14-21 days.
* **PJP Prophylaxis:** 5 mg/kg/day of trimethoprim component, given in 2 divided doses PO daily.
Actual pediatric dosing may vary based on the specific indication and formulation used. Always consult age- and weight-appropriate guidelines.
## Dose Adjustments
* **Renal Impairment:** Adjust dose based on creatinine clearance (CrCl).
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Half the usual dose.
* CrCl < 15 mL/min: Avoid use.
* **Hepatic Impairment:** Use with caution. No specific dose adjustment is typically recommended, but monitoring of liver function may be warranted.
## Contraindications
* Known hypersensitivity to trimethoprim, sulfonamides, or any component of the formulation.
* Infants younger than 2 months of age (risk of kernicterus).
* Documented megaloblastic anemia due to folate deficiency.
* Severe renal insufficiency (CrCl < 15 mL/min) or hepatic insufficiency.
* History of drug-induced thrombocytopenia with sulfonamides or trimethoprim.
## Adverse Effects
* **Common:** Nausea, vomiting, rash (including Stevens-Johnson syndrome/toxic epidermal necrolysis, which can be severe and life-threatening), pruritus, diarrhea, headache, hyperkalemia.
* **Less Common:** Leukopenia, thrombocytopenia, eosinophilia, eosinophilia, crystalluria, photosensitivity, glossitis, stomatitis.
## Key Drug Interactions
* **Warfarin:** Co-trimoxazole may increase INR. Monitor INR closely and adjust warfarin dose as needed.
* **Potassium-Sparing Diuretics (e.g., spironolactone, amiloride):** Increased risk of hyperkalemia.
* **ACE Inhibitors/ARBs:** Increased risk of hyperkalemia.
* **Methotrexate:** Co-trimoxazole may increase methotrexate levels, increasing the risk of toxicity.
* **Cyclosporine:** Co-trimoxazole may increase cyclosporine levels, increasing the risk of nephrotoxicity.
* **Digoxin:** Co-trimoxazole may increase digoxin levels, particularly in patients with impaired renal function.
* **Oral Hypoglycemics:** May potentiate hypoglycemia.
## Monitoring
* **Renal function:** Especially in patients with pre-existing renal impairment or those taking other nephrotoxic agents.
* **Complete blood counts (CBC):** Regularly, especially with prolonged therapy, in elderly patients, or those with G6PD deficiency. Monitor for signs of hematologic toxicity.
* **Electrolytes:** Particularly potassium, especially in patients with renal impairment or those taking other medications that affect potassium levels.
* **Skin:** Monitor for rash, which can be a sign of serious hypersensitivity reactions. Discontinue immediately if rash develops.
* **Hydration:** Ensure adequate fluid intake to prevent crystalluria.
## Clinical Pearls
* Administer with a full glass of water to prevent crystalluria.
* Patients with G6PD deficiency are at increased risk of hemolytic anemia.
* Sulfonamides can displace bilirubin from albumin in neonates, leading to kernicterus; therefore, it is contraindicated in infants younger than 2 months.
* Advise patients to report any rash, fever, sore throat, or unusual bleeding/bruising immediately.
***
*This information is intended for clinical use and does not replace current prescribing information. Always verify with the most up-to-date official drug labeling and institutional protocols before administering any medication.*
